Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1980 Feb;55(2):89–98. doi: 10.1136/adc.55.2.89

Drug level monitoring in paediatric practice.

G W Rylance, T A Moreland
PMCID: PMC1626686  PMID: 6990880

Full text

PDF
89

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agurell S., Berlin A., Ferngren H., Hellström B. Plasma levels of diazepam after parenteral and rectal administration in children. Epilepsia. 1975 Jun;16(2):277–283. doi: 10.1111/j.1528-1157.1975.tb06058.x. [DOI] [PubMed] [Google Scholar]
  2. Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121–134. doi: 10.1002/cpt1970111121. [DOI] [PubMed] [Google Scholar]
  3. BUCHTHAL F., SVENSMARK O., SCHILLER P. J. Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin. Arch Neurol. 1960 Jun;2:624–630. doi: 10.1001/archneur.1960.03840120030004. [DOI] [PubMed] [Google Scholar]
  4. BUTLER T. C., WADDELL W. J. Metabolic conversion of primidone (mysoline) to phenobarbital. Proc Soc Exp Biol Med. 1956 Dec;93(3):544–546. doi: 10.3181/00379727-93-22813. [DOI] [PubMed] [Google Scholar]
  5. Bacon C. J., Mucklow J. C., Saunders A., Rawlins M. D., Webb J. K. A method for obtaining saliva samples from infants and young children. Br J Clin Pharmacol. 1978 Jan;5(1):89–90. doi: 10.1111/j.1365-2125.1978.tb01604.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Black S. B., Levine P., Shinefield H. R. The necessity for monitoring chloramphenicol levels when treating neonatal meningitis. J Pediatr. 1978 Feb;92(2):235–236. doi: 10.1016/s0022-3476(78)80013-4. [DOI] [PubMed] [Google Scholar]
  7. Bloxham R. A., Durbin G. M., Johnson T., Winterborn M. H. Chloramphenicol and phenobarbitone--a drug interaction. Arch Dis Child. 1979 Jan;54(1):76–77. doi: 10.1136/adc.54.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bochner F., Hooper W. D., Sutherland J. M., Eadie M. J., Tyrer J. H. Diphenylhydantoin concentrations in saliva. Arch Neurol. 1974 Jul;31(1):57–59. doi: 10.1001/archneur.1974.00490370083014. [DOI] [PubMed] [Google Scholar]
  9. Borofsky L. G., Louis S., Kutt H., Roginsky M. Diphenylhydantoin: efficacy, toxicity, and dose-serum level relationships in children. J Pediatr. 1972 Nov;81(5):995–1002. doi: 10.1016/s0022-3476(72)80561-4. [DOI] [PubMed] [Google Scholar]
  10. Buchanan R. A., Turner J. L., Moyer C. E., Heffelfinger J. C. Single daily dose of diphenylhydantoin in children. J Pediatr. 1973 Sep;83(3):479–483. doi: 10.1016/s0022-3476(73)80281-1. [DOI] [PubMed] [Google Scholar]
  11. Buchthal F., Svensmark O. Serum concentrations of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects. Psychiatr Neurol Neurochir. 1971 Mar-Apr;74(2):117–136. [PubMed] [Google Scholar]
  12. Buchthal F., Svensmark O., Simonsen H. Relation of eeg and seizures to phenobarbital in serum. Arch Neurol. 1968 Dec;19(6):567–572. doi: 10.1001/archneur.1968.00480060037004. [DOI] [PubMed] [Google Scholar]
  13. Butler V. P., Jr Assays of digitalis in the blood. Prog Cardiovasc Dis. 1972 May;14(6):571–600. doi: 10.1016/0033-0620(72)90009-6. [DOI] [PubMed] [Google Scholar]
  14. Calabro J. J. Management of juvenile rheumatoid arthritis. J Pediatr. 1970 Sep;77(3):355–365. doi: 10.1016/s0022-3476(70)80001-4. [DOI] [PubMed] [Google Scholar]
  15. Cook C. E., Amerson E., Poole W. K., Lesser P., O'Tuama L. Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay. Clin Pharmacol Ther. 1975 Dec;18(6):742–747. doi: 10.1002/cpt1975186742. [DOI] [PubMed] [Google Scholar]
  16. Curless R. G., Walson P. D., Carter D. E. Phenytoin kinetics in children. Neurology. 1976 Aug;26(8):715–720. doi: 10.1212/wnl.26.8.715. [DOI] [PubMed] [Google Scholar]
  17. Dahlgren J. G., Anderson E. T., Hewitt W. L. Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother. 1975 Jul;8(1):58–62. doi: 10.1128/aac.8.1.58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Danhof M., Breimer D. D. Therapeutic drug monitoring in saliva. Clin Pharmacokinet. 1978 Jan-Feb;3(1):39–57. doi: 10.2165/00003088-197803010-00003. [DOI] [PubMed] [Google Scholar]
  19. Darrell J. H., Waterworth P. M. Dosage of gentamicin for pseudomonas infections. Br Med J. 1967 May 27;2(5551):535–537. doi: 10.1136/bmj.2.5551.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Dvorchik B. H., Vesell E. S. Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clin Chem. 1976 Jun;22(6):868–878. [PubMed] [Google Scholar]
  21. EAGLE H., FLEISCHMAN R., LEVY M. "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med. 1953 Mar 19;248(12):481–488. doi: 10.1056/NEJM195303192481201. [DOI] [PubMed] [Google Scholar]
  22. Eadie M. J. Plasma level monitoring of anticonvulsants. Clin Pharmacokinet. 1976;1(1):52–66. doi: 10.2165/00003088-197601010-00005. [DOI] [PubMed] [Google Scholar]
  23. Echeverria P., Siber G. R., Paisley J., Smith A. L., Smith D. H., Jaffe N., Paed D. Age-dependent dose response to gentamicin. J Pediatr. 1975 Nov;87(5):805–808. doi: 10.1016/s0022-3476(75)80316-7. [DOI] [PubMed] [Google Scholar]
  24. Eichelbaum M., Ekbom K., Bertilsson L., Ringberger V. A., Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975 Jun 13;8(5):337–341. doi: 10.1007/BF00562659. [DOI] [PubMed] [Google Scholar]
  25. Elion G. B., Kovensky A., Hitchings G. H. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase. Biochem Pharmacol. 1966 Jul;15(7):863–880. doi: 10.1016/0006-2952(66)90163-8. [DOI] [PubMed] [Google Scholar]
  26. Ellis E. F., Koysooko R., Levy G. Pharmacokinetics of theophylline in children with asthma. Pediatrics. 1976 Oct;58(4):542–547. [PubMed] [Google Scholar]
  27. Evans W. E., Feldman S., Barker L. F., Ossi M., Chaudhary S. Use of gentamicin serum levels to individualize therapy in children. J Pediatr. 1978 Jul;93(1):133–137. doi: 10.1016/s0022-3476(78)80626-x. [DOI] [PubMed] [Google Scholar]
  28. Faero O., Kastrup K. W., Lykkegaard Nielsen E., Melchior J. C., Thorn I. Successful prophylaxis of febrile convulsions with phenobarbital. Epilepsia. 1972 Apr;13(2):279–285. doi: 10.1111/j.1528-1157.1972.tb05262.x. [DOI] [PubMed] [Google Scholar]
  29. Fitzgerald J. D., O'Donnell S. R. Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br J Pharmacol. 1971 Sep;43(1):222–235. doi: 10.1111/j.1476-5381.1971.tb07171.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Frigerio A., Morselli P. L. Carbamazepine: biotransformation. Adv Neurol. 1975;11:295–308. [PubMed] [Google Scholar]
  31. Gallagher B. B., Smith D. B., Mattson R. H. The relationship of the anticonvulsant properties of primidone to phenobarbital. Epilepsia. 1970 Sep;11(3):293–301. doi: 10.1111/j.1528-1157.1970.tb03893.x. [DOI] [PubMed] [Google Scholar]
  32. Garrettson L. K., Dayton P. G. Disappearance of phenobarbital and diphenylhydantoin from serum of children. Clin Pharmacol Ther. 1970 Sep-Oct;11(5):674–679. doi: 10.1002/cpt1970115674. [DOI] [PubMed] [Google Scholar]
  33. Garrettson L. K., Jusko W. J. Diphenylhydantoin elimination kinetics in overdosed children. Clin Pharmacol Ther. 1975 Apr;17(4):481–491. doi: 10.1002/cpt1975174481. [DOI] [PubMed] [Google Scholar]
  34. Gerber N., Lynn R., Oates J. Acute intoxication with 5,5-diphenylhydantoin (Dilantin) associated with impairment of biotransformation. Plasma levels and urinary metabolites; and studies in healthy volunteers. Ann Intern Med. 1972 Nov;77(5):765–771. doi: 10.7326/0003-4819-77-5-765. [DOI] [PubMed] [Google Scholar]
  35. Ginchansky E., Weinberger M. Relationship of theophylline clearance to oral dosage in children with chronic asthma. J Pediatr. 1977 Oct;91(4):655–660. doi: 10.1016/s0022-3476(77)80527-1. [DOI] [PubMed] [Google Scholar]
  36. Gram L., Flachs H., Würtz-Jørgensen A., Parnas J., Andersen B. Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia. 1979 Jun;20(3):303–311. doi: 10.1111/j.1528-1157.1979.tb04808.x. [DOI] [PubMed] [Google Scholar]
  37. Haigh D., Forsythe W. I. The treatment of childhood epilepsy with sodium valproate. Dev Med Child Neurol. 1975 Dec;17(6):743–748. doi: 10.1111/j.1469-8749.1975.tb04698.x. [DOI] [PubMed] [Google Scholar]
  38. Hambleton G., Weinberger M., Taylor J., Cavanaugh M., Ginchansky E., Godfrey S., Tooley M., Bell T., Greenberg S. Comparison of cromoglycate (cromolyn) and theophylline in controlling symptoms of chronic asthma. A collaborative study. Lancet. 1977 Feb 19;1(8008):381–385. doi: 10.1016/s0140-6736(77)92601-0. [DOI] [PubMed] [Google Scholar]
  39. Hayes C. J., Butler V. P., Jr, Gersony W. M. Serum digoxin studies in infants and children. Pediatrics. 1973 Oct;52(4):561–568. [PubMed] [Google Scholar]
  40. Heckmatt J. Z., Houston A. B., Clow D. J., Strephenson J. B., Dodd K. L., Lealman G. T., Logan R. W. Failure of phenobarbitone to prevent febrile convulsions. Br Med J. 1976 Mar 6;1(6009):559–561. doi: 10.1136/bmj.1.6009.559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Heimann G., Gladtke E. Pharmacokinetics of phenobarbital in childhood. Eur J Clin Pharmacol. 1977 Dec 2;12(4):305–310. doi: 10.1007/BF00607431. [DOI] [PubMed] [Google Scholar]
  42. Hooper W. D., Bochner F., Eadie M. J., Tyrer J. H. Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease. Clin Pharmacol Ther. 1974 Mar;15(3):276–282. doi: 10.1002/cpt1974153276. [DOI] [PubMed] [Google Scholar]
  43. Horning M. G., Brown L., Nowlin J., Lertratanangkoon K., Kellaway P., Zion T. E. Use of saliva in therapeutic drug monitoring. Clin Chem. 1977 Feb;23(2 Pt 1):157–164. [PubMed] [Google Scholar]
  44. Huffman D. H. Relationship between digoxin concentrations in serum and saliva. Clin Pharmacol Ther. 1975 Mar;17(3):310–312. doi: 10.1002/cpt1975173310. [DOI] [PubMed] [Google Scholar]
  45. Ingelfinger J. A., Goldman P. The serum digitalis concentration--does it diagnose digitalis toxicity? N Engl J Med. 1976 Apr 15;294(16):867–870. doi: 10.1056/NEJM197604152941603. [DOI] [PubMed] [Google Scholar]
  46. Jackson G. G., Arcieri G. Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. J Infect Dis. 1971 Dec;124 (Suppl):S130–S137. doi: 10.1093/infdis/124.supplement_1.s130. [DOI] [PubMed] [Google Scholar]
  47. Jackson G. G., Riff L. J. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis. 1971 Dec;124 (Suppl):S185–S191. doi: 10.1093/infdis/124.supplement_1.s185. [DOI] [PubMed] [Google Scholar]
  48. Jeavons P. M., Clark J. E., Maheshwari M. C. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate ("epilim"). Dev Med Child Neurol. 1977 Feb;19(1):9–25. doi: 10.1111/j.1469-8749.1977.tb08015.x. [DOI] [PubMed] [Google Scholar]
  49. Jenkins J. S., Sampson P. A. The conversion of cortisone to cortisol and prednisone to prednisolone in man. Proc R Soc Med. 1966 Jul;59(7):603–604. [PMC free article] [PubMed] [Google Scholar]
  50. Jones R. A., Baillie E. Dosage schedule for intravenous aminophylline in apnoea of prematurity, based on pharmacokinetic studies. Arch Dis Child. 1979 Mar;54(3):190–193. doi: 10.1136/adc.54.3.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Jusko W. J., Gerbracht L., Golden L. H., Koup J. R. Digoxin concentrations in serum and saliva. Res Commun Chem Pathol Pharmacol. 1975 Jan;10(1):189–192. [PubMed] [Google Scholar]
  52. Knudsen F. U. Plasma-diazepam in infants after rectal administration in solution and by suppository. Acta Paediatr Scand. 1977 Sep;66(5):563–567. doi: 10.1111/j.1651-2227.1977.tb07947.x. [DOI] [PubMed] [Google Scholar]
  53. Koch-Weser J., Duhme D. W., Greenblatt D. J. Influence of serum digoxin concentration measurements on frequency of digitoxicity. Clin Pharmacol Ther. 1974 Jul;16(1):284–287. doi: 10.1002/cpt1974161part2284. [DOI] [PubMed] [Google Scholar]
  54. Krasula R. W., Hastreiter A. R., Levitsky S., Yanagi R., Soyka L. F. Serum, atrial, and urinary digoxin levels during cardiopulmonary bypass in children. Circulation. 1974 Jun;49(6):1047–1052. doi: 10.1161/01.cir.49.6.1047. [DOI] [PubMed] [Google Scholar]
  55. Lai A. A., Levy R. H., Cutler R. E. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther. 1978 Sep;24(3):316–323. doi: 10.1002/cpt1978243316. [DOI] [PubMed] [Google Scholar]
  56. Levy A. M., Leaman D. M., Hanson J. S. Effects of digoxin on systolic time intervals of neonates and infants. Circulation. 1972 Oct;46(4):816–823. doi: 10.1161/01.cir.46.4.816. [DOI] [PubMed] [Google Scholar]
  57. Levy G., Ellis E. F., Koysooko R. Indirect plasma-theophylline monitoring in asthmatic children by determination of theophylline concentration in saliva. Pediatrics. 1974 Jun;53(6):873–876. [PubMed] [Google Scholar]
  58. Levy G., Koysooko R. Pharmacokinetic analysis of the effect of theophylline on pulmonary function in asthmatic children. J Pediatr. 1975 May;86(5):789–793. doi: 10.1016/s0022-3476(75)80374-x. [DOI] [PubMed] [Google Scholar]
  59. Loiseau P., Brachet A., Henry P. Concentration of dipropylacetate in plasma. Epilepsia. 1975 Nov;16(4):609–615. doi: 10.1111/j.1528-1157.1975.tb04743.x. [DOI] [PubMed] [Google Scholar]
  60. Loughnan P. M., Sitar D. S., Ogilvie R. I., Eisen A., Fox Z., Neims A. H. Pharmacokinetic analysis of the disposition of intravenous theophylline in young children. J Pediatr. 1976 May;88(5):874–879. doi: 10.1016/s0022-3476(76)81136-5. [DOI] [PubMed] [Google Scholar]
  61. Lund L. Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures. Arch Neurol. 1974 Nov;31(5):289–294. doi: 10.1001/archneur.1974.00490410037002. [DOI] [PubMed] [Google Scholar]
  62. Lund L., Berlin A., Lunde K. M. Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid. Clin Pharmacol Ther. 1972 Mar-Apr;13(2):196–200. doi: 10.1002/cpt1972132196. [DOI] [PubMed] [Google Scholar]
  63. MARSHALL E. K., Jr, OWENS A. H., Jr Absorption, excretion and metabolic fate of chloral hydrate and trichloroethanol. Bull Johns Hopkins Hosp. 1954 Jul;95(1):1–18. [PubMed] [Google Scholar]
  64. Matin S. B., Wan S. H., Karam J. H. Pharmacokinetics of tolbutamide: prediction by concentration in saliva. Clin Pharmacol Ther. 1974 Dec;16(6):1052–1058. doi: 10.1002/cpt19741661052. [DOI] [PubMed] [Google Scholar]
  65. McAllister T. A. Clinical bacteriology of tobramycin. Scott Med J. 1976 Apr;21(2):64–66. doi: 10.1177/003693307602100208. [DOI] [PubMed] [Google Scholar]
  66. McAllister T. A., Tait S. C. Laboratory findings of tobramycin and their relation to clinical response. J Infect Dis. 1976 Aug;134 (Suppl):S20–S27. doi: 10.1093/infdis/134.supplement_1.s20. [DOI] [PubMed] [Google Scholar]
  67. McAuliffe J. J., Sherwin A. L., Leppik I. E., Fayle S. A., Pippenger C. E. Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology. 1977 May;27(5):409–413. doi: 10.1212/wnl.27.5.409. [DOI] [PubMed] [Google Scholar]
  68. McKenzie M. W., Stewart R. B., Weiss C. F., Cluff L. E. A pharmacist-based study of the epidemiology of adverse drug reactions in pediatric medicine patients. Am J Hosp Pharm. 1973 Oct;30(10):898–903. [PubMed] [Google Scholar]
  69. McKenzie S. A., Edmunds A. T., Baillie E., Meek J. H. Clinical applications of serum theophylline measurement by high pressure liquid chromatography. Arch Dis Child. 1978 Apr;53(4):322–325. doi: 10.1136/adc.53.4.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. McKenzie S., Baillie E. Serum theophylline levels in asthmatic children after oral administration of two slow-release theophylline preparations. Arch Dis Child. 1978 Dec;53(12):943–946. doi: 10.1136/adc.53.12.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Meinardi H., Van Der Kleijn E., Meijer J. W., Van Rees H. Absorption and distribution of antiepileptic drugs. Epilepsia. 1975 Jun;16(2):353–365. doi: 10.1111/j.1528-1157.1975.tb06063.x. [DOI] [PubMed] [Google Scholar]
  72. Monaco F., Riccio A., Benna P., Covacich A., Durelli L., Fantini M., Furlan P. M., Gilli M., Mutani R., Troni W. Further observations on carbamazepine plasma levels in epileptic patients. Relationships with therapeutic and side effects. Neurology. 1976 Oct;26(10):936–973. doi: 10.1212/wnl.26.10.936. [DOI] [PubMed] [Google Scholar]
  73. Moreland T. A., Rylance G. W., Christopher L. J., Stevenson I. H. Patterns of drug prescribing for children in hospital. Eur J Clin Pharmacol. 1978 Nov 9;14(1):39–46. doi: 10.1007/BF00560256. [DOI] [PubMed] [Google Scholar]
  74. Morselli P. L., Frigerio A. Metabolism and Pharmacolinetics of Carbamazepine. Drug Metab Rev. 1975;4(1):97–113. doi: 10.3109/03602537508993750. [DOI] [PubMed] [Google Scholar]
  75. Mucklow J. C., Bending M. R., Kahn G. C., Dollery C. T. Drug concentration in saliva. Clin Pharmacol Ther. 1978 Nov;24(5):563–570. doi: 10.1002/cpt1978245563. [DOI] [PubMed] [Google Scholar]
  76. Mäkela A. L., Yrjänä T., Mattila M. Dosage of salicylates for children with juvenile rheumatoid arthritis. A prospective clinical trial with three different preparations of acetylsalicylic acid. Acta Paediatr Scand. 1979 May;68(3):423–430. doi: 10.1111/j.1651-2227.1979.tb05031.x. [DOI] [PubMed] [Google Scholar]
  77. Noone P., Parsons T. M., Pattison J. R., Slack R. C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J. 1974 Mar 16;1(5906):477–481. doi: 10.1136/bmj.1.5906.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Norell E., Lilienberg G., Gamstorp I. Systematic determination of the serum phenytoin level as an aid in the management of children with epilepsy. Eur Neurol. 1975;13(3):232–244. doi: 10.1159/000114679. [DOI] [PubMed] [Google Scholar]
  79. O'Malley K., Coleman E. N., Doig W. B., Stevenson I. H. Plasma digoxin levels in infants. Arch Dis Child. 1973 Jan;48(1):55–57. doi: 10.1136/adc.48.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Odar-Cederlöf I., Lunde P., Sjöqvist F. Abnormal pharmacokinetics of phenytoin in a patient with uraemia. Lancet. 1970 Oct 17;2(7677):831–832. doi: 10.1016/s0140-6736(70)91506-0. [DOI] [PubMed] [Google Scholar]
  81. Overturf G. D., Wehrle P. F. Bacterial meningitis: which regimen? Drugs. 1979 Jul;18(1):65–73. doi: 10.2165/00003495-197918010-00006. [DOI] [PubMed] [Google Scholar]
  82. Paxton J. W., Whiting B., Stephen K. W. Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay. Br J Clin Pharmacol. 1977 Apr;4(2):185–191. doi: 10.1111/j.1365-2125.1977.tb00692.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Pinsky W. W., Jacobsen J. R., Gillette P. C., Adams J., Monroe L., McNamara D. G. Dosage of digoxin in premature infants. J Pediatr. 1979 Apr;94(4):639–642. doi: 10.1016/s0022-3476(79)80041-4. [DOI] [PubMed] [Google Scholar]
  84. Pippenger C. E., Penry J. K., White B. G., Daly D. D., Buddington R. Interlaboratory variability in determination of plasma antiepileptic drug concentrations. Arch Neurol. 1976 May;33(5):351–355. doi: 10.1001/archneur.1976.00500050037007. [DOI] [PubMed] [Google Scholar]
  85. Raine P. A., Young D. G. Tobramycin in paediatric use. Scott Med J. 1976 Apr;21(2):66–67. doi: 10.1177/003693307602100209. [DOI] [PubMed] [Google Scholar]
  86. Randall L. O., Scheckel C. L., Banziger R. F. Pharmacology of the metabolites of chlordiazepoxide and diazepam. Curr Ther Res Clin Exp. 1965 Sep;7(9):590–606. [PubMed] [Google Scholar]
  87. Rane A., Höjer B., Wilson J. T. Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. Clin Pharmacol Ther. 1976 Mar;19(3):276–283. doi: 10.1002/cpt1976193276. [DOI] [PubMed] [Google Scholar]
  88. Reidenberg M. M., Odar-Cederlöf I., von Bahr C., Borgå O., Sjöqvist F. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med. 1971 Jul 29;285(5):264–267. doi: 10.1056/NEJM197107292850506. [DOI] [PubMed] [Google Scholar]
  89. Remmer H., Hirschmann J., Greiner I. Die Bedeutung von Kumulation und Elimination für die Dosierung von Phenytoin (Diphenylhydantoin) Dtsch Med Wochenschr. 1969 Jun 13;94(24):1265–1272. doi: 10.1055/s-0028-1111205. [DOI] [PubMed] [Google Scholar]
  90. Richens A., Warrington S. When should plasma drug levels be monitored? Drugs. 1979 Jun;17(6):488–500. doi: 10.2165/00003495-197917060-00005. [DOI] [PubMed] [Google Scholar]
  91. Rylance G. W., Butcher G. M., Moreland T. Saliva carbamazepine levels in children. Br Med J. 1977 Dec 3;2(6100):1481–1481. doi: 10.1136/bmj.2.6100.1481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Rylance G. W., Moreland T. A., Butcher G. M. Carbamazepine dose-frequency requirement in children. Arch Dis Child. 1979 Jun;54(6):454–458. doi: 10.1136/adc.54.6.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. SVENSMARK O., BUCHTHAL F. DIPHENYLHYDANTOIN AND PHENOBARBITAL. SERUM LEVELS IN CHILDREN. Am J Dis Child. 1964 Jul;108:82–87. doi: 10.1001/archpedi.1964.02090010084011. [DOI] [PubMed] [Google Scholar]
  94. Salivary concentrations of antiepileptic drugs. Lancet. 1976 Sep 18;2(7986):639–640. [PubMed] [Google Scholar]
  95. Sawchuk R. J., Zaske D. E., Cipolle R. J., Wargin W. A., Strate R. G. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther. 1977 Mar;21(3):362–369. doi: 10.1002/cpt1977213362. [DOI] [PubMed] [Google Scholar]
  96. Schentag J. J., Jusko W. J., Plaut M. E., Cumbo T. J., Vance J. W., Abrutyn E. Tissue persistence of gentamicin in man. JAMA. 1977 Jul 25;238(4):327–329. [PubMed] [Google Scholar]
  97. Schmidt D., Kupferberg J. Diphenylhydantoin, phenobarbital, and primidone in saliva, plasma, and cerebrospinal fluid. Epilepsia. 1975 Dec;16(5):735–741. doi: 10.1111/j.1528-1157.1975.tb04758.x. [DOI] [PubMed] [Google Scholar]
  98. Schobben F., van der Kleijn E., Gabreëls F. J. Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur J Clin Pharmacol. 1975 Feb 28;8(2):97–105. doi: 10.1007/BF00561557. [DOI] [PubMed] [Google Scholar]
  99. Shannon D. C., Gotay F., Stein I. M., Rogers M. C., Todres I. D., Moylan F. M. Prevention of apnea and bradycardia in low-birthweight infants. Pediatrics. 1975 May;55(5):589–594. [PubMed] [Google Scholar]
  100. Sheiner L. B. The use of serum concentrations of digitalis for quantitative therapeutic decisions. Cardiovasc Clin. 1974;6(2):141–151. [PubMed] [Google Scholar]
  101. Sherwin A. L., Robb J. P., Lechter M. Improved control of epilepsy by monitoring plasma ethosuximide. Arch Neurol. 1973 Mar;28(3):178–181. doi: 10.1001/archneur.1973.00490210058007. [DOI] [PubMed] [Google Scholar]
  102. Shoeman D. W., Azarnoff D. L. The alteration of plasma proteins in uremia as reflected in their ability to bind digitoxin and diphenylhydantoin. Pharmacology. 1972;7(3):169–177. doi: 10.1159/000136286. [DOI] [PubMed] [Google Scholar]
  103. Siber G. R., Echeverria P., Smith A. L., Paisley J. W., Smith D. H. Pharmacokinetics of gentamicin in children and adults. J Infect Dis. 1975 Dec;132(6):637–651. doi: 10.1093/infdis/132.6.637. [DOI] [PubMed] [Google Scholar]
  104. Simonsen N., Olsen P. Z., Kühl V., Lund M., Wendelboe J. A comparative controlled study between carbamazepine and diphenylhydantoin in psychomotor epilepsy. Epilepsia. 1976 Jun;17(2):169–176. doi: 10.1111/j.1528-1157.1976.tb03394.x. [DOI] [PubMed] [Google Scholar]
  105. Smith T. W. Digitalis toxicity: epidemiology and clinical use of serum concentration measurements. Am J Med. 1975 Apr;58(4):470–476. doi: 10.1016/0002-9343(75)90118-7. [DOI] [PubMed] [Google Scholar]
  106. Speirs C. F. Tobramycin side effects-international results. Scott Med J. 1976 Apr;21(2):78–78. doi: 10.1177/003693307602100215. [DOI] [PubMed] [Google Scholar]
  107. Strandjord R. E., Johannessen S. I., Halpern L. M. One daily dose of diphenylhydantoin for patients with epilepsy. Epilepsia. 1974 Sep;15(3):317–327. doi: 10.1111/j.1528-1157.1974.tb04011.x. [DOI] [PubMed] [Google Scholar]
  108. TRIEDMAN H. M., FISHMAN R. A., YAHR M. D. Determination of plasma and cerebrospinal fluid levels of dilantin in the human. Trans Am Neurol Assoc. 1960;85:166–170. [PubMed] [Google Scholar]
  109. Taylor M., Keane C. Gentamicin dosage in children. Arch Dis Child. 1976 May;51(5):369–372. doi: 10.1136/adc.51.5.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Troupin A. S., Green J. R., Halpern L. M. Carbamazepine (Tegretol) as an anticonvulsant. A controlled double-blind comparison with diphenylhydantoin (Dilantin). Acta Neurol Scand Suppl. 1975;60:13–26. doi: 10.1111/j.1600-0404.1975.tb01383.x. [DOI] [PubMed] [Google Scholar]
  111. Van Meter J. C., Buckmaster H. S., Shelley L. L. Concurrent assay of phenobarbital and diphenylhydantoin in plasma by vapor-phase chromatography. Clin Chem. 1970 Feb;16(2):135–138. [PubMed] [Google Scholar]
  112. Weinberger M. M., Bronsky E. A. Evaluation of oral bronchodilator therapy in asthmatic children. Bronchodilators in asthmatic children. J Pediatr. 1974 Mar;84(3):421–427. doi: 10.1016/s0022-3476(74)80732-8. [DOI] [PubMed] [Google Scholar]
  113. Weinberger M., Bronsky E., Bensch G. W., Bock G. N., Yecies J. J. Interaction of ephedrine and theophylline. Clin Pharmacol Ther. 1975 May;17(5):585–592. doi: 10.1002/cpt1975175585. [DOI] [PubMed] [Google Scholar]
  114. Weinberger M., Ginchansky E. Dose-dependent kinetics of theophylline disposition in asthmatic children. J Pediatr. 1977 Nov;91(5):820–824. doi: 10.1016/s0022-3476(77)81051-2. [DOI] [PubMed] [Google Scholar]
  115. Westenberg H. G., de Zeeuw R. A., van de Kleijn E., Oei T. T. Relationship between carbamazepine concentrations in plasma and saliva in man as determined by liquid chromatography. Clin Chim Acta. 1977 Aug 15;79(1):155–161. doi: 10.1016/0009-8981(77)90473-9. [DOI] [PubMed] [Google Scholar]
  116. Windorfer A., Jr, Pringsheim W. Studies on the concentrations of chloramphenicol in the serum and cerebrospinal fluid of neonates, infants, and small children. Reciprocal reactions between chloramphenicol, penicillin and phenobarbitone. Eur J Pediatr. 1977 Jan 26;124(2):129–138. doi: 10.1007/BF00477548. [DOI] [PubMed] [Google Scholar]
  117. Wulff K., Flachs H., Würtz-Jorgensen A., Gram L. Clinical pharmacological aspects of valproate sodium. Epilepsia. 1977 Jun;18(2):149–157. doi: 10.1111/j.1528-1157.1977.tb04463.x. [DOI] [PubMed] [Google Scholar]
  118. Zwillich C. W., Sutton F. D., Neff T. A., Cohn W. M., Matthay R. A., Weinberger M. M. Theophylline-induced seizures in adults. Correlation with serum concentrations. Ann Intern Med. 1975 Jun;82(6):784–787. doi: 10.7326/0003-4819-82-6-784. [DOI] [PubMed] [Google Scholar]
  119. van der Klejin E., van Rossum J. M., Muskens E. T., Rijntjes N. V. Pharmacokinetics of diazepam in dogs, mice and humans. Acta Pharmacol Toxicol (Copenh) 1971;29 (Suppl 3):109–127. doi: 10.1111/j.1600-0773.1971.tb03291.x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES